Arcutis Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARQT research report →
Companywww.arcutis.com
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
- CEO
- Todd Franklin Watanabe
- IPO
- 2020
- Employees
- 342
- HQ
- Westlake Village, CA, US
Price Chart
Valuation
- Market Cap
- $2.56B
- P/E
- -1114.52
- P/S
- 6.16
- P/B
- 13.96
- EV/EBITDA
- 198.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.94%
- Op Margin
- 0.77%
- Net Margin
- -0.57%
- ROE
- -1.41%
- ROIC
- 1.05%
Growth & Income
- Revenue
- $376.07M · 91.34%
- Net Income
- $-16,140,999 · 88.47%
- EPS
- $-0.13 · 88.79%
- Op Income
- $-12,227,000
- FCF YoY
- 94.38%
Performance & Tape
- 52W High
- $31.77
- 52W Low
- $12.72
- 50D MA
- $22.91
- 200D MA
- $23.25
- Beta
- 1.59
- Avg Volume
- 1.55M
Get TickerSpark's AI analysis on ARQT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Vairavan Latha | sell | 435 |
| May 11, 26 | Burnett Patrick | sell | 222 |
| May 4, 26 | Matsuda Masaru | sell | 7,372 |
| May 4, 26 | Matsuda Masaru | sell | 884 |
| May 4, 26 | Burnett Patrick | sell | 684 |
| May 4, 26 | Vairavan Latha | sell | 1,341 |
| May 4, 26 | Watanabe Todd | sell | 3,172 |
| May 1, 26 | Welgus Howard G. | sell | 7,144 |
| Apr 1, 26 | Welgus Howard G. | sell | 10,000 |
| Mar 2, 26 | Leonard Keith R | other | 12,220 |
Our ARQT Coverage
We haven't published any research on ARQT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARQT Report →